This site is for US health care professionals only.
Farydak® (Panobinostat) is being voluntarily withdrawn from the US market
A REMS (Risk Evaluation and Mitigation Strategy) is a program required by the FDA to manage known or potential serious risks associated with a drug product. The FDA has determined that a REMS is necessary to ensure that the benefits of FARYDAK® (panobinostat) outweigh the risks.
FARYDAK has a Boxed WARNING for the following risks: